Reports
Explore our work below:
The cost of comparison: When the benchmark becomes the barrier
A central pillar of Australia’s Health Technology Assessment (HTA) system is comparative evaluation, where a medicine or vaccine is assessed for clinical and economic value against a given comparator.
Transforming lives: Making haemophilia B gene therapy a reality in Australia
Haemophilia B is a rare, genetic disorder that turns even minor injuries into serious health risks. [1] Due to the absence of clotting factor IX…
Change that can’t wait: Reducing the human and economic burden of COPD in Australia
Chronic obstructive pulmonary disease (COPD) is one of Australia’s most common chronic diseases, and yet one of the most overlooked in our national health…
When Nations Compete: Why ‘Most Favoured Nation’ matters for medicine access in Australia
Most Favoured Nation (MFN) pricing, a longstanding principle of international trade, has entered the pharmaceutical…
Invisible Brain Cancers: Living with the social and economic impact of IDH-mutant glioma
For far too long, the impacts of isocitrate dehydrogenase (IDH)-mutant glioma, a rare and incurable brain cancer, have been overshadowed by better-known…
Every moment matters: Addressing the human and economic toll of motor neurone disease in Australia
Motor neurone disease (MND) is a progressive neurodegenerative condition that disrupts communication…
Out of the shadow: Transforming care for people living with hypophosphatasia
Hypophosphatasia (HPP) is a genetic, multisystem condition that impairs the body’s ability to properly mineralise…
Confronting cholesterol: Bringing it all together to solve Australia’s ASCVD crisis
Atherosclerotic cardiovascular disease (ASCVD) is a major contributor to cardiovascular disease (CVD) burden…
Navigating The Unknown: A call for nationwide brain cancer care coordination
Each year, approximately 2,000 Australian babies, children and adults are…
Diagnosis to dignity: A vision for Alzheimer’s disease in Australia
Alzheimer’s disease is one of the most significant health challenges of our time, with the potential…
Bench to bedside: the promise of radioligand therapy
Radioligand therapy advancements are set to support the next phase in cancer care with their precision medicine approach
Breaking the cycle: Insights from the Inherited Cancers Australia community
Hereditary cancer cuts across generations, casting a shadow…
Closing the medicine gap: Improving First Nations peoples’ access to medicine
At Evohealth, we are dedicated to advancing health equity for all Australians…
Prioritising prevention: Addressing the burden of pneumococcal disease in Australia
As a leading health advisory firm, we recognise the urgency of addressing…
Changing lives: Improving access to blood cancer treatments in Australia
A trio of blood cancers are killing Australians. These cancers affect…
Beyond Burnout: Supporting our General Practitioners
As the gateway to our health system, the demand and pressure on General Practitioners (GPs)…
Fighting Superbugs: Ensuring Australia is ready to combat the rise of drug resistant infections
Evohealth is proud to partner with the Australian Antimicrobial Resistance Network…
Cell and gene therapies: Rising to the challenge Scorecard 2023
Cell and Gene Therapies, or CGTs, are at the forefront of medical innovation. Unlike conventional medicines…
Time to Act: protecting our children from RSV
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for Australian infants and children under 5…
Connecting Nurses to Nurses
With our proximity to the equator, high proportion of fair skinned people and enjoyment of the great outdoors…
CAR T-cell therapy: Is Australia ready, willing and able?
Multiple myeloma is a devastating and incurable disease affecting thousands of Australians and their families…
Preparing Australia: Designing an Australian Centre for Disease Control (CDC)
For many Australians, the COVID-19 pandemic has been their defining experience of public health in action…
Shining a light: Radiotherapy cancer treatment in Australia
In Australia, there is one new cancer diagnosis every four minutes. Australia spends over $10 billion per year…
ASCVD in Taiwan: A public health priority
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality globally – and yet, if identified early…
Cell and gene therapies: Rising to the challenge
Cell and gene therapies (CGTs) are changing the way that care is delivered to patients around the world…
Australia’s Cholesterol Heartache
Australia has become cholesterol complacent. This complacency is putting Australians living with cardiovascular disease (CVD) at risk…